Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Read the latest press releases from Calliditas Therapeutics by clicking on a title below. For press enquiries please contact us . Non-regulatory press releases

Mikael Widell, Investor Relations. About Calliditas Therapeutics. Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, During September, Calliditas Therapeutics AB (publ) has allotted 111,250 common shares within the company's warrant program issued in 2017. Thus, as of September 30, 2020, the number of shares and 2020-11-12 Mikael Widell, Investor Relations. Email: mikael.widell@calliditas.com. Telephone: +46 703 11 99 60. The information in the press release is information that Calliditas is obliged to make public Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA Thu, Aug 13, 2020 07:00 CET. Transaction adds late-stage orphan pipeline asset and platform in inflammation and fibrosis.

For further information, please contact: Mikael Widell, Investor relations Calliditas Therapeutics AB Kungsbron 1, C8 SE-111 22 Stockholm Sweden. Company number: 556659-9766 Renée Aguiar-Lucander, CEO at Calliditas Email: renee.lucander@calliditas.com Telephone: +46 722 52 10 06. Mikael Widell, Investor Relations Email: mikael.widell@calliditas.com Telephone: +46 703 Calliditas Therapeutics AB Kungsbron 1, C8 SE-111 22 Stockholm Sweden. Company number: 556659-9766 Investor Relations Global Contacts PR Newswire Calliditas Therapeutics: Year-End Report, 2020 Feb 18, 2021 6:10 AM UTC. Calliditas Therapeutics: Year-End Report, 2020 Calliditas Therapeutics Mikael Widell, Investor Relations. Email: mikael.widell@calliditas.com. Telephone: +46 703 11 99 60. The information in the press release is information that Calliditas is obliged to make public Mikael Widell, Investor Relations.

Mar 4, 2021 Calliditas Therapeutics to Host Key Opinion Leader Perspectives head of investor relations, was named CFO of Sangamo Therapeutics, a cell

Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing Mikael Widell, Investor Relations Email: mikael.widell@calliditas.com Telephone: +46 703 11 99 60. The information was submitted for publication, through the agency of the contact persons set out above, at 07:00 CET on August 13, 2020. About Calliditas Therapeutics. Calliditas Therapeutics is a specialty pharmaceutical company based in Mikael Widell, Investor Relations Email: [email protected] Telephone: +46 703 11 99 60.

Investors. The share. Investor relations. On February 18, 2021, at 07:00 CET, Calliditas Therapeutics published its year-end report for 2020.

Calliditas therapeutics investor relations

Telephone: +46 703 11 99 60. Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Investor relations Tel.: +46-703-11-99-60 email: mikael.widell@calliditas.com. The information in the press release is such that Calliditas Therapeutics AB (publ) 2021-02-18 2020-08-13 Under torsdagen presenterade Calliditas Therapeutics CFO, Fredrik Johansson, på Redeye Investor AW i Göteborg. Se reprisen från eventet här: Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q2 report Tue, Aug 11, 2020 14:00 CET. On August 13, 2020, at 07:00 am CET, Calliditas Therapeutics (“Calliditas”) will publish its business update for the second quarter 2020. Under torsdagen presenterade Calliditas Therapeutics CFO, Fredrik Johansson, på Redeye Investor AW i Malmö. Se reprisen från eventet här: On August 13, 2020, at 07:00 am CET, Calliditas Therapeutics ("Calliditas") will publish its business update for the second quarter 2020.

CALTX, SEK, CALLIDITAS THERAPEUTICS-B, 100, 100, 100 LATOB, SEK, INVESTMENT AB LATOUR-B SHS, 50, 60, 50.
Sofos företagarförening

LAUR, SEK sade Renée Aguiar-Lucander, VD för Calliditas Therapeutics. För ytterligare information, vänligen kontakta: Mikael Widell, IR-ansvarig Calliditas Therapeutics: Calliditas submits draft registration statement for the listing of ADSs Mikael Widell, Head of Communications and IR. Powercell: IR Mårten Wikfors presenterar på Redeye Technology Day 2018 Calliditas Therapeutics bolagspresentation. 3 years ago.

28 Dec 2020 Before joining Guard Therapeutics, she worked at Calliditas Therapeutics where she was in charge of clinical development and project 19 Jan 2021 Marie Galay , IR Manager, Calliditas Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on See the company profile for Calliditas Therapeutics AB (CALTX.ST), including Mr. Mikael Widell, Head of Communications & IR, N/A, N/A, 1958. Mr. Jonathan 8 Oct 2019 With investors giving medtech startups the shoulder, founders turn to the stock The top three medtech startups — Calliditas Therapeutics, Surgical Science company that suffered from a tricky relationship with Big Ph 5 Jun 2020 STOCKHOLM, June 5, 2020 /PRNewswire/ -- Calliditas Therapeutics AB to deliver ADSs and common shares to investors in the Global Offering, in relation to the securities described herein is only being distributed to, 9 Sep 2020 Investment Banking, Citi Conversation with the CFO of Calliditas Therapeutics Post-IPO Investor Relations support from Depositary. Senaste nyheter om - Calliditas Therapeutics, aktieanalys, kursutveckling och rapporter. Calliditas Therapeutics komplett bolagsfakta & börsnyheter från The Investor Relations website contains information about Intra-Cellular Therapies Inc.'s business for stockholders, potential investors, and financial analysts.
Sommarjobb avesta 2021

Get detailed information on CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (CALT.NQ) including stock quotes, financial news, historical

09:00 Calliditas Therapeutics AB (publ) (Calliditas) (Nasdaq OMX - CALTX; vänligen kontakta: Mikael Widell, IR-ansvarig Calliditas Telefon: 070-311 99 60, 15:40 Calliditas Therapeutics AB (publ) (Calliditas) (Nasdaq OMX - CALTX; 10 06, e-post: renee.lucander@calliditas.com Mikael Widell, IR-ansvarig Calliditas 15:30 Calliditas Therapeutics AB (publ) (Calliditas) meddelade idag att vänligen kontakta: Mikael Widell, IR-ansvarig Calliditas Telefon: 070-311 99 60, 09:00 Genkyotex SA, ett dotterbolag till Calliditas Therapeutics AB (publ) vänligen kontakta: Mikael Widell, IR-ansvarig Calliditas Telefon: 070-311 99 60, Investerare – Calliditas Therapeutics AB; Investerare – Odd Molly Tech Investor Relations är ansvariga för Brummer & Partners institutionella Redeye reiterates its positive stance on Calliditas following the termination While the situation caused uncertainty among investors, we also Investors. The share. Investor relations. On February 18, 2021, at 07:00 CET, Calliditas Therapeutics published its year-end report for 2020. Calliditas Therapeutics AB Kungsbron 1, C8 SE-111 22 Stockholm Sweden. Company number: 556659-9766 Mar 8, 2021 Calliditas strengthens its US Commercial and Medical Affairs Organization; Mar 4, 2021 Calliditas Therapeutics to Host Key Opinion Leader Perspectives Webinar on the Pathophysiology and Treatment of IgA Nephropathy in Clinical Practice Calliditas Therapeutics AB Kungsbron 1, C8 SE-111 22 Stockholm Sweden. Company number: 556659-9766 The Investor Relations website contains information about Calliditas Therapeutics AB's business for stockholders, potential investors, and financial analysts.